SILENCE THERAPEUTICS PLC
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
T&Cs apply
About SLN
Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.
$298.52M
-
0.00%
302.37K
$6.51
$6.20
$6.44
$8.08
$1.97
Ready to start your investing journey with Stake?
Open an accountSLN FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in SLN
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in SLN
on Stake
Buy SLN from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of SLN from only US$10 with fractional shares
